Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyMedical Mutual - Ohio 5‑FU TDM Coverage | OpenPaye…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy AHS - M2067

    Therapeutic Drug Monitoring for 5‑Fluorouracil

    Customize your policy alerts

    Sign up for medical mutual - ohio Policy AHS - M2067 alerts

    Get alerted when Policy AHS - M2067 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage stance for therapeutic drug monitoring to guide dosing of intravenous 5-fluorouracil (5-FU) for individuals receiving 5-FU chemotherapy and lists tests that do not meet coverage. Affects providers requesting TDM services under Medical Mutual - Ohio benefits.

    Policy Summary
    Payermedical mutual - ohio
    PolicyTherapeutic Drug Monitoring for 5‑Fluorouracil
    Policy CodePolicy AHS - M2067
    Change TypeAdministrative review — no material coverage changes
    Effective Date06/01/2026
    Last ReviewDec 3, 2025
    Next Review DateN/A
    Key ActionWhen requesting authorization, document that the patient is receiving 5‑FU chemotherapy and that TDM (AUC measurement) is requested to guide dose adjustment; include DPYD genotype or DPD phenotype results when available.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20–30 mg×h/LAUC target
    58%After TDM (PREDICT-5FU)
    36%With BSA dosing (PREDICT-5FU)
    S3722, 80299, 82542, 83789Procedure codes listed
    12/03/2025Last review

    Coverage Criteria for 5‑FU Therapeutic Drug Monitoring

    Covered Indication — 5-FU TDM

    Covered when ALL of the following are met:

    Indication: Individual is undergoing 5-fluorouracil (5-FU) chemotherapy and therapeutic drug monitoring (TDM) is requested to aid in dose adjustment.

    Policy statement: TDM to aid dose adjustment meets coverage criteria.

    Therapeutic approach: AUC-based TDM is planned and will be used to guide dosing adjustments to achieve target systemic exposure (target AUC 20-30 mg×h/L).AUC target 20-30 mg×h/L

    Target AUC range referenced in scientific background and policy.

    Biomarker and baseline assessment: Clinician documents DPYD genotype or DPD phenotype (uracil/uracilemia) results, or documents rationale for proceeding with TDM when genotype/phenotype testing is unavailable or not performed.

    Guideline-aligned recommendation to assess DPYD/DPD status to inform dosing and TDM interpretation.

    TDM use and follow-up: AUC measurements will be obtained and explicitly used to adjust dosing per a defined TDM protocol, with clinical follow-up for toxicity monitoring and dose titration based on AUC and adverse events.

    Coverage supports use of AUC measurement to guide dose titration and clinical monitoring.

    Regimen applicability: Individual is receiving an intravenous continuous infusion 5‑FU regimen (or capecitabine conversion where applicable) for which AUC-guided dose optimization is intended.

    Policy covers infusional 5-FU regimens where AUC measurement and dose optimization are applied.

    Not covered tests

    Not covered:

    Not covered tests: Uracil breath tests

    Listed explicitly as not meeting coverage criteria due to lack of published scientific literature.

    Not covered tests: Dihydrouracil/uracil ratio testing of plasma, serum, or urine

    Listed explicitly as not meeting coverage criteria due to lack of published scientific literature.

    The policy explicitly excludes certain approaches to assessing fluoropyrimidine exposure or DPD activity. Specifically, uracil breath tests and dihydrouracil/uracil ratio testing of plasma, serum, or urine do not meet coverage criteria for managing dose adjustment of 5‑fluorouracil due to insufficient published scientific literature demonstrating they are required and beneficial for diagnosis or treatment.

    Patients known to have complete DPD (dihydropyrimidine dehydrogenase) deficiency should not receive 5‑fluorouracil or related fluoropyrimidine substances. The European Medicines Agency (PRAC) concluded that benefit–risk is negative in patients with complete DPD deficiency and that these medicinal products are contraindicated in this population; patients with partial deficiency require adjusted starting doses.

    A literature review was completed as part of the policy update and the review did not necessitate any modification to the existing coverage criteria for therapeutic drug monitoring of 5‑fluorouracil; prior authorization and coverage requirements therefore remain unchanged.

    Although this policy supports Therapeutic Drug Monitoring (TDM) to guide AUC‑based dose adjustment for patients receiving intravenous 5‑FU when documented genotype/phenotype assessment and AUC measurements are used, not all guideline sources uniformly endorse routine TDM. The NCCN guidelines do not address TDM for 5‑FU in disease‑specific guidance and include no AUC‑based dosing recommendations for 5‑FU, and the NICE review states the My5‑FU assay shows promise but should be recommended only for research purposes. These guideline positions are reflected in the policy’s mixed stance: TDM for 5‑FU meets coverage criteria when used in an evidence‑based, guideline‑aligned manner with appropriate documentation, but some assays and contexts remain investigational or limited in scope per external guidance.

    Regimens Covered with AUC-guided TDM

    Regimen / SettingIndication for AUC-guided dose adjustment
    Continuous intravenous 5‑fluorouracil (5‑FU) infusion (single‑agent or combination regimens)Dose adjustment when therapeutic drug monitoring (AUC) shows exposure outside target range (target AUC 20–30 mg×h/L) to reduce toxicity and optimize efficacy; used when clinician requests TDM to aid titration.
    Standard BSA‑based 5‑FU infusion regimens where interpatient variability is suspected or prior toxicity occurredPost‑therapy or between‑cycle AUC measurement to guide upward or downward dose titration to achieve target AUC 20–30 mg×h/L, consistent with trial and guideline practice.
    Capecitabine with conversion to equivalent 5‑FU exposure (when managed clinically as part of TDM protocol)When capecitabine exposure is being monitored via equivalent 5‑FU AUC calculations and dose optimization is required to reach target AUC 20–30 mg×h/L.
    Example regimen / scenarioNotes / examples of measurement or conversion
    Continuous‑infusion 5‑FU (eg, regimens used in colorectal or head‑and‑neck cancer)AUC (mg×h/L) measured from serial plasma sampling each cycle; adjust subsequent cycle dose per TDM protocol to reach 20–30 mg×h/L (IATDMCT guidance; clinical trials target range).
    5‑FU containing combination regimens (eg, FOLFOX, FOLFIRI) using continuous infusion componentMonitor infusion 5‑FU AUC and titrate infusion dose within the combination regimen to achieve target exposure and minimize grade 3–4 toxicity, as supported by randomized and observational studies.
    Patients initially dosed by BSA who demonstrate subtherapeutic or supratherapeutic exposureApply PK‑guided adjustments: studies (Wilhelm; PREDICT‑5FU) show many patients miss target AUC with BSA dosing and that TDM improves proportion achieving 20–30 mg×h/L after adjustment.
    Capecitabine regimens where clinicians convert oral dosing to expected 5‑FU exposure for monitoringSerial sampling and calculated equivalent 5‑FU AUC used to inform capecitabine dose modifications under a TDM protocol (PREDICT‑5FU feasibility data).

    Procedure and Assay Codes

    Applicable CPT/HCPCS procedure codesCPT
    No codes listed
    Procedure and assay codes for 5‑FU TDM and related testingCPT
    S3722Dose optimization by area under the curve (AUC) analysis, for infusional 5-fluorouracil
    80299Quantitation of therapeutic drug, not elsewhere specified
    82542Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen
    83789Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen
    5‑FU Target Exposure
    Recommended 5-FU target AUC20-30 mg×h/L

    Provider Actions, Documentation & Authorization Guidance

    Prior Authorization

    TDM for 5‑FU meets coverage when used to aid dose adjustment

    Therapeutic drug monitoring (TDM) for individuals undergoing 5‑fluorouracil (5‑FU) chemotherapy meets coverage criteria when requested to aid in dose adjustment.

    Billing Rule

    Procedure codes for authorization and billing

    Use procedure code S3722 (dose optimization by AUC analysis for infusional 5‑FU) and the listed assay codes (80299, 82542, 83789) as references when submitting authorization requests and for billing related TDM services.

    • S3722 — Dose optimization by AUC analysis, for infusional 5‑fluorouracil
    • 80299 — Quantitation of therapeutic drug, not elsewhere specified

    Biomarker and Phenotype Requirements for Testing

    DPD / Uracil Phenotyping Threshold
    Uracil (uracilemia) phenotyping cutoff reported in studyU > 16 ng/mL referenced as a cutoff in one study
    DPYD/DPD Genotype and Phenotype Categories (per CPIC)
    DPYD activity-score categoriesCPIC defines DPYD activity-score categories (intermediate and poor metabolizers) to guide dosing and recommends follow-up TDM when genotype-based dose reductions are applied
    DPYD poor metabolizersDPYD-AS: 0.5 or 0 — CPIC strongly recommends avoiding 5‑FU; if no alternative, give strongly reduced dose with early TDM
    DPYD intermediate metabolizersReduce starting dose based on activity score and titrate based on toxicity or TDM (if available)

    Definitions

    Definition: 5‑FU
    5-FU5-fluorouracil
    SynonymFU (fluorouracil)
    Route commonly discussedIntravenous continuous infusion
    Definition: AUC
    AUCArea-under-curve (drug exposure over time)
    Clinical useAccepted metric of systemic 5‑FU exposure used for TDM
    Target for 5‑FUTarget AUC 20-30 mg×h/L

    Background and Evidence Summary

    5‑Fluorouracil (5‑FU) is a commonly used intravenous chemotherapeutic agent with a narrow therapeutic index. Conventional body surface area (BSA) dosing shows substantial interpatient variability in systemic exposure, which can lead to underexposure or excessive toxicity. Therapeutic drug monitoring (TDM) using area‑under‑the‑curve (AUC)–guided dosing is intended to optimize systemic exposure; the policy references a target exposure range of 20–30 mg×h/L as the goal for AUC‑based 5‑FU dose individualization to improve efficacy and reduce high‑grade toxicity.

    Supporting guideline and evidence summaries note divergent positions: some specialty groups and pharmacology consortia support genotype/phenotype assessment and implementation of AUC‑based TDM in appropriate clinical settings, while major guideline bodies vary in their endorsements. Specifically, the policy cites that NCCN does not include TDM for 5‑FU in its disease‑specific guidelines, and NICE recommends the My5‑FU assay only for research purposes. These contextual statements were used to align the coverage stance with the current guideline landscape.

    Revision History

    2025-12-03policy_reviewLatest

    Reviewed and updated background, guidelines, and evidence-based scientific references; literature review did not necessitate modifications to coverage criteria.

    Policy Summary
    Payermedical mutual - ohio
    PolicyTherapeutic Drug Monitoring for 5‑Fluorouracil
    Policy CodePolicy AHS - M2067
    Change TypeAdministrative review — no material coverage changes
    Effective Date06/01/2026
    Last ReviewDec 3, 2025
    Next Review DateN/A
    Key ActionWhen requesting authorization, document that the patient is receiving 5‑FU chemotherapy and that TDM (AUC measurement) is requested to guide dose adjustment; include DPYD genotype or DPD phenotype results when available.
    SourceLink
    On This Page
    Coverage Criteria for 5‑FU Therapeutic Drug MonitoringRegimens Covered with AUC-guided TDMProcedure and Assay CodesProvider Actions, Documentation & Authorization GuidanceBiomarker and Phenotype Requirements for TestingDefinitionsBackground and Evidence SummaryRevision History
  1. 82542 — Column chromatography (eg, HPLC, LC/MS) when performed
  2. 83789 — Mass spectrometry and tandem mass spectrometry assays
  3. Prior Authorization

    Prior authorization requirements remain unchanged

    The policy review updated background and references but did not change prior authorization requirements; existing prior authorization processes remain in effect.

    Note
    Step Therapy

    Sequence genotyping/phenotyping before treatment and use TDM for titration

    Guidance recommends performing DPYD genotyping or DPD phenotyping before initiating fluoropyrimidine therapy and using therapeutic drug monitoring (AUC-based TDM) for dose titration and follow-up when genotype-guided dose reductions are applied or when titration is required.

    • Genotype/phenotype assessment (DPYD or uracil/uracilemia) is recommended before FP-based chemotherapy (EMA/CPIC/STP-PT guidance).
    • Follow-up AUC-based TDM is recommended to titrate doses after genotype-guided reductions or when dose escalation is considered.
    Note

    Clinical guidance sources inform testing sequence

    Clinical guidance documents (CPIC, SFPT/GPCO-Unicancer, STP-PT and EMA assessments) inform recommended sequencing of DPD genotyping/phenotyping prior to fluoropyrimidine initiation and the use of TDM for dose optimization thereafter.

    • CPIC 2017 guidance recommends genotype-informed dosing with follow-up TDM when dose reductions are applied.
    • SFPT/GPCO-Unicancer and STP-PT recommend implementation of 5‑FU TDM to ensure adequate exposure.
    • EMA recommends DPD testing before initiation of FP-based chemotherapy.
    Documentation Required

    Document clinical indication: undergoing 5‑FU chemotherapy and TDM for dose adjustment

    Document that the individual is currently receiving 5‑fluorouracil chemotherapy and that TDM is being requested specifically to aid dose adjustment.

    • Include statement of active 5‑FU chemotherapy in the clinical indication.
    • Explain that the purpose of the TDM request is to guide dose adjustment.
    Documentation Required

    Include genotype/phenotype results and AUC measures in documentation

    Include DPYD genotype results or DPD phenotype (uracil/uracilemia) results and any available therapeutic drug monitoring AUC measurements in authorization documentation.

    • Provide DPYD genotype or DPD phenotype (uracil) test results, if performed.
    • Include AUC values from TDM and note how results will be used to adjust dosing.
    Documentation Required

    Supportive evidence to include with requests

    Attach relevant supportive evidence when submitting TDM authorization requests, such as NICE reviews, CPIC guidance, SFPT/GPCO-Unicancer/STP-PT recommendations, EMA assessments, and applicable FDA product labeling.

    • NICE review of My5‑FU assay
    • CPIC 2017 DPYD guideline
    • SFPT/GPCO-Unicancer and STP-PT recommendations
    • EMA PRAC assessment on fluorouracil
    • FDA product labeling where applicable
    Denial Risk

    Uracil breath tests and dihydrouracil/uracil ratio testing are not covered

    Requests for uracil breath tests and dihydrouracil/uracil ratio testing for managing 5‑FU dose adjustment do not meet coverage criteria and may be denied.

    • Uracil breath tests are explicitly listed as not meeting coverage.
    • Dihydrouracil/uracil ratio testing of plasma, serum, or urine is explicitly listed as not meeting coverage.
    Denial Risk

    5‑FU contraindicated in known complete DPD deficiency (EMA)

    Use of 5‑fluorouracil (and related substances) is contraindicated in patients with known complete DPD deficiency per the EMA assessment; such cases should not be authorized for 5‑FU therapy.

    • EMA concluded products are contra‑indicated in patients with complete DPD deficiency.
    • Patients with partial DPD deficiency should be treated with adjusted starting doses per EMA.
    Prior Authorization

    No changes to authorization criteria after literature review

    The literature review and policy update did not require changes to the coverage or authorization criteria; continue to apply existing authorization rules.

    DPD (short summary)
    DPD (dihydropyrimidine dehydrogenase)Enzyme responsible for catabolism of fluoropyrimidines; testing guidance (CPIC) referenced for genotype to guide dosing
    Clinical roleAssessment of DPD status used to identify patients at increased risk of 5‑FU toxicity
    Testing methodsDPYD genotyping and uracil-based phenotyping cited as suitable methods (EMA PRAC)
    Definition: TDM
    TDMTherapeutic drug monitoring
    PurposeMeasuring drug concentrations to maintain constant therapeutic exposure and optimize dosing
    ApplicationUsed for 5‑FU to reduce toxicity and improve efficacy via AUC-guided dosing
    Definition: DPD/DPYD
    DPD / DPYDDihydropyrimidine dehydrogenase (enzyme involved in 5‑FU catabolism)
    SignificanceDeficiency increases risk of severe 5‑FU toxicity; testing recommended before therapy per EMA/CPIC
    Testing approachesGenotyping for DPYD variants and uracil phenotyping (uracilemia)
    Definition: AUC (policy context)
    AUC as 5‑FU exposure metricArea under the curve (AUC) is the accepted metric of systemic 5‑FU exposure used for TDM
    Relationship to outcomesIATDMCT and other groups report correlations between 5‑FU AUC and both efficacy and toxicity
    Use in dosingAUC values guide pharmacokinetically‑guided dose adjustments for 5‑FU
    Definition: Assessment of DPD deficiency
    DPD deficiency assessmentAssessment via DPYD genotyping or uracil‑based phenotyping to identify patients at increased risk of 5‑FU toxicity
    PurposeTo inform dose reductions or alternative therapy selection prior to fluoropyrimidine treatment
    Regulatory noteEMA recommends DPD testing before initiation of FP-based chemotherapy
    Definition: DPD testing and CPIC guidance
    DPD testing and CPIC guidanceCPIC guideline provides genotype-based dosing recommendations and advises follow-up TDM when genotype-based dose reductions are used
    Genotype-driven dosingCPIC defines activity-score based dose adjustments for DPYD intermediate and poor metabolizers
    Phenotype useUracil phenotyping is cited alongside genotyping as a method to detect DPD deficiency (EMA/ETIENNE‑GRIMALDI review)